版本:
中国

BRIEF-Roche receives FDA approval for complementary pd-l1 biomarker test in Urothelial Carcinoma

May 2 Roche Holding Ag

* Roche receives FDA approval for Complementary PD-l1 (SP263) Biomarker test in Urothelial carcinoma

* Continues to pursue regulatory approval for Ventana PD-l1 assay in other cancer indications in US and in other geographies Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐